Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Alpha-1 antitrypsin (AAT) deficiency is well-suited as a target for human gene transfer. We performed a phase 1, open-label, dose-escalation clinical trial of a recombinant adeno-associated virus (rAAV) vector expressing normal (M) AAT packaged into serotype 1 AAV capsids delivered by i.m. injection. Nine AAT-deficient subjects were enrolled sequentially in cohorts of 3 each at doses of 6.9 × 10 12 , 2.2 × 10 13 , and 6.0 × 10 13 vector genome particles per patient. Four subjects receiving AAT protein augmentation discontinued therapy 28 or 56 days before vector administration. Vector administration was well tolerated, with only mild local reactions and 1 unrelated serious adverse event (bacterial epididymitis). There were no changes in hematology or clinical chemistry parameters. M-specific AAT was expressed above background in all subjects in cohorts 2 and 3 and was sustained at levels 0.1% of normal for at least 1 year in the highest dosage level cohort, despite development of neutralizing antibody and IFN-γ enzyme-linked immunospot responses to AAV1 capsid at day 14 in all subjects. These findings suggest that immune responses to AAV capsid that develop after i.m. injection of a serotype 1 rAAV vector expressing AAT do not completely eliminate transduced cells in this context.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, other trials have observed T-cell immune responses that did not clear transgene expression, particularly muscle-directed trials [86, 90, 91].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [90]
In the citing paper
“Despite the observation of immune responses after intravenous (i.v.) administration of AAV, concurrent clinical trials using intramuscular (i.m.) delivery of AAV revealed long-term transgene expression without immune suppression, regardless of significant immune cell infiltration.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [7]
In the citing paper
“whereas muscle-directed AAV gene therapy clinical trials have shown long-lived transgene expression and induction of Tregs.7,8,11,51”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [7]
In the citing paper
“have been implicated in contributing to long-term transgene expression in preclinical studies (35, 160, 161) and clinical trials (162 -164).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [162]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“This complexity also comes into play when comparing our data with that in the rAAV2–factor IX clinical trial (14).”
BackgroundResultHIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Betts, M. R. (2006) · Blood · doi:10.1182/blood-2005-12-4818 · Cited by 1,826
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 3×
“33, which is unexpected on the basis of animal immunization studies that indicate few shared B cell epitopes between these AAVs (18, 19).”
BackgroundInfluentialSelf-citationWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“Consistent with previously published results (16), antibodies to AAV7 and AAV8 were detected at baseline infrequently (in 2 of 9 subjects, both of whom had received the rAAV2 vector in a previous study) and antibodies to AAVrh32.”
ResultSelf-citationNovel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696 · cited 1×
“other Ad helper genes and the AAV1 rep and cap genes (23).”
BackgroundKessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Self-citationProduction and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Self-citationAdeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · cited 3×
“33, which is unexpected on the basis of animal immunization studies that indicate few shared B cell epitopes between these AAVs (18, 19).”
BackgroundInfluentialSelf-citationSong, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B. J., Atkinson, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14384 · Cited by 304 · cited 1×
“Because of a marked efficiency advantage for vectors packaged in AAV serotype 1 capsid and injected in murine muscle, our group proceeded with preclinical development of a cross-packaged or pseudotyped rAAV–AAT vector, using the same rAAV–AAT gene cassette as in the previous clinical trial but packaged in a serotype 1…”
MethodSelf-citationThe Alpha1-antitrypsin Gene and Its Mutations
Crystal, R. G., Brantly, M. L., Hubbard, R. C., Curiel, D. T., States, D. J., & Holmes, M. D. (1989) · Chest · doi:10.1378/chest.95.1.196 · Cited by 209
Self-citation
Research works printed but not linked: 2
- 10.1016/s0002-9343(88)80069-x · doi:10.1016/s0002-9343(88)80069-x
- A Poirier, et al., Toxicology and biodistribution studies of a recombinant adeno-associated virus 2-α1-antitrypsin vector. Preclinica 2, 43–51 (2004).
Cited by
Items 101–200 of 349
Carrillo-Carrasco, N., Chandler, R. J., Chandrasekaran, S., & Venditti, C. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.008 · Cited by 54
“, 2006) and a1-antitrypsin deficiency (Brantly et al., 2009).”
Greig, J. A., Peng, H., Ohlstein, J., Medina-Jaszek, C. A., Ahonkhai, O., Mentzinger, A., Grant, R. L., Roy, S., Chen, S.-J., Bell, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112268 · Cited by 55
“Vectors derived from adeno-associated viruses (AAV) have been shown to produce long-term and stable gene expression of secreted proteins in a variety of animal models and human clinical trials following intramuscular (IM) injection, including coagulation factor IX (FIX) [1,2,3,4,5], alpha-1-antitrypsin (AAT) [6,7], er…”
BackgroundInfluentialSelf-citationAugmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies
Tonelli, A. R., & Brantly, M. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810373911 · Cited by 58
“In this open-label, dose-escalation trial of gene augmentation through intramuscular injection, a reproducible and sustained expression of wild-type M-AAT was observed in the group of patients that received the highest dosage, despite T lymphocyte responses [Brantly et al. 2009].”
BackgroundSelf-citationBinny, C., McIntosh, J., Della Peruta, M., Kymalainen, H., Tuddenham, E. G. D., Buckley, S. M. K., Waddington, S. N., McVey, J. H., Spence, Y., Morton, C. L., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377630 · Cited by 54
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Chiuchiolo, M. J., Kaminsky, S. M., Sondhi, D., Hackett, N. R., Rosenberg, J. B., Frenk, E. Z., Hwang, Y., Van de Graaf, B. G., Hutt, J. A., Wang, G., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.168 · Cited by 53
“The plasma a 1AT protective threshold of 11 l M has been the target of the ongoing clinical trials that use intra-muscular delivery of either AAV1 or AAV2 (Brantly et al. , 2006, 2009; Mueller and Flotte, 2013).”
InfluentialSomanathan, S., Jacobs, F., Wang, Q., Hanlon, A. L., Wilson, J. M., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.115.304008 · Cited by 54
Self-citationNi, W., Guiner, C. L., Gernoux, G., Penaud‐Budloo, M., Moullier, P., & Snyder, R. O. (2011) · Gene Therapy · doi:10.1038/gt.2011.19 · Cited by 54
Lin, J., Calcedo, R., Vandenberghe, L. H., Figueredo, J. M., & Wilson, J. M. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.033 · Cited by 53
Self-citationXiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Self-citationRebuffat, A., Harding, C. O., Ding, Z., & Thöny, B. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.127 · Cited by 53
“The appearance of vector DNA in blood was followed by rapid clearance to low or undetectable levels within 7 to 14 days after the injection and similar outcome has also been observed in two clinical trials (Brantly et al. , 2009; Mingozzi et al. , 2009).”
Greig, J. A., Calcedo, R., Grant, R. L., Peng, H., Medina-Jaszek, C. A., Ahonkhai, O., Qin, Q., Roy, S., Tretiakova, A. P., & Wilson, J. M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.053 · Cited by 53
Self-citationHumoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Gorovits, B., Azadeh, M., Buchlis, G., Fiscella, M., Harrison, T., Havert, M., Janetzki, S., Jawa, V., Long, B. R., Mahnke, Y. D., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00814-5 · Cited by 52
“Examples include development of cellular immune response in AAV vector-treated hemophilia A and B, LPL deficiency, alpha-1-antitrypsin (AAT) deficiency, early-onset severe retinal dystrophy, and Duchenne muscular dystrophy patients (9-11, 23, 24, 27, 33-36).”
BackgroundThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Yuan, Z., Qiao, C., Hu, P., Li, J., & Xiao, X. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.241 · Cited by 42
“…using AAV vectors to treat genetic diseases such as hemophilia (Margaritis and High, 2010), muscular dystrophy (Wang et al., 2000; Chamberlain, 2002; Mendell et al., 2009, 2010a,b), Leber’s congenital amaurosis (Maguire et al., 2008, 2009), and alpha-1 antitrypsin deficiency (Brantly et al., 2009).”
MethodGene therapy for alpha-1 antitrypsin deficiency
Flotte, T. R., & Mueller, C. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr156 · Cited by 48
Self-citationGene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease
Chiuchiolo, M. J., & Crystal, R. G. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201506-344kv · Cited by 50
Ferla, R., Alliegro, M., Marteau, J., Dell’Anno, M., Nusco, E., Pouillot, S., Galimberti, S., Valsecchi, M. G., Zuliani, V., & Auricchio, A. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.004 · Cited by 51
The future potential for cocaine vaccines
Orson, F. M., Wang, R., Brimijoin, S., Kinsey, B. M., Singh, R. A., Ramakrishnan, M., Wang, H. Y., & Kosten, T. R. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.920319 · Cited by 49
Recent advances in α-1-antitrypsin deficiency-related lung disease
Brebner, J., & Stockley, R. A. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/ers.13.20 · Cited by 49
A review of augmentation therapy for alpha-1 antitrypsin deficiency
Mohanka, M. R., Khemasuwan, D., & Stoller, J. K. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.676638 · Cited by 49
“0 10 [83].”
Li, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Byrne, B. J., Smith, B., Mah, C., Lawson, L. A., Islam, S., Corti, M., Martin, D., Dobija, N., Irwin, M. V., Conlon, T., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.2514 · Cited by 46
“Currently, the trial of AAV-1 expressing alph-1 antitrypsin has been completed at our institution, with no adverse events reported (Brantly et al., 2009).”
Self-citationTargeted Gene Therapy for the Treatment of Heart Failure
Rapti, K., Chaanine, A. H., & Hajjar, R. J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.02.005 · Cited by 48
Alpha1-antitrypsin deficiency: New therapies on the horizon
Remih, K., Amzou, S., & Strnad, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.001 · Cited by 48
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Servais, L., Horton, R. H., Saade, D., Bönnemann, C. G., Muntoni, F., Adjali, O., Beggs, A. H., Bharucha, D., Bönnemann, C. G., Braun, S., et al. (2023) · Neuromuscular Disorders · doi:10.1016/j.nmd.2023.09.008 · Cited by 47
Self-citationAssaying the Stability and Inactivation of AAV Serotype 1 Vectors
Howard, D. B., & Harvey, B. K. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.180 · Cited by 47
Guilbaud, M., Devaux, M., Couzinié, C., Le Duff, J., Toromanoff, A., Vandamme, C., Jaulin, N., Gernoux, G., Larcher, T., Moullier, P., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.234 · Cited by 45
Okada, T., & Takeda, S. (2013) · Pharmaceuticals · doi:10.3390/ph6070813 · Cited by 45
“Also, a phase 1, open-label, dose-escalation clinical trial using an AAV-1 vector expressing normal AAT by intramuscular injection was performed [36].”
BackgroundAdipose tissue-derived mesenchymal stem cell-based liver gene delivery
Li, H., Zhang, B., Lu, Y., Jorgensen, M., Petersen, B. E., & Song, S. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.051 · Cited by 45
“[5,30,52-54] For AAT deficiency-associated liver disease, no effective therapy is available except liver organ transplantation which is hampered by a shortage of donor organs.”
BackgroundArjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
“Steroids are commonly used in AAV trials for broad immunosuppression; however, they do not specifically target capsid-specific T cells,65 and may also deplete Tregs.66 In contrast, AAV-CAR Tregs provide selective immune modulation activated specifically by AAV capsid, creating a local immunosuppressive environment in…”
ResultInfluentialSelf-citationPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
“In some cases, existence of capsid-specific CTLs did not significantly impact correction as seen in AAT studies involving intramuscular (IM) injections (10).”
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Genetic and metabolic liver disease
Thompson, R. J., Portmann, B. C., & Roberts, E. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00004-0 · Cited by 43
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
Wang, Y.-J., Gao, C.-Y., Yang, M., Liu, X.-H., Sun, Y., Pollard, A., Dong, X.-Y., Wu, X.-B., Zhong, J.-H., Zhou, H.-D., et al. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.05.010 · Cited by 41
“lar injection of rAAV1 carrying alpha-1 antitrypsin (ATT) was also well tolerated with sustained transgene expression in a small cohort of ATT-deficiency patients (Brantly et al., 2009).”
BackgroundAlpha-1 antitrypsin deficiency
Dasí, F. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.10.014 · Cited by 41
Bisserier, M., Sun, X., Fazal, S., Turnbull, I. C., Bonnet, S., & Hadri, L. (2022) · Cells · doi:10.3390/cells11060984 · Cited by 41
Measuring Immune Responses to Recombinant AAV Gene Transfer
Martino, A. T., Herzog, R. W., Anegon, I., & Adjali, O. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_11 · Cited by 36
β‐cell‐specific IL‐35 therapy suppresses ongoing autoimmune diabetes in NOD mice
Manzoor, F., Johnson, M. C., Li, C., Samulski, R. J., Wang, B., & Tisch, R. (2016) · European Journal of Immunology · doi:10.1002/eji.201646493 · Cited by 39
“AAV vectors, in conjugation with a number of capsid protein serotypes with varying cell tropism and tissue specific promoters, offer an approach to selectively transduce distinct tissues and obtain long-term cell-specific transgene expression in vivo [27, 31, 32].”
BackgroundWerder, R. B., Kaserman, J. E., Packer, M. S., Lindstrom-Vautrin, J., Villacorta-Martín, C., Young, L. E., Aratyn-Schaus, Y., Gregoire, F. M., & Wilson, A. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.021 · Cited by 39
“Among these, early human clinical trials delivering a normal copy of the SERPINA1 gene to skeletal muscle have achieved long-term but sub-therapeutic production of normal “M-AAT” protein.(8,9) Although promising, this strategy does not rectify toxic gainof-function effects in Z-AAT-expressing hepatocytes.”
BackgroundGenetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
The unfolded protein response to PI*Z alpha‐1 antitrypsin in human hepatocellular and murine models
Lu, Y., Wang, L. R., Lee, J., Mohammad, N. S., Aranyos, A. M., Gould, C., Khodayari, N., Oshins, R. A., Moneypenny, C. G., & Brantly, M. (2022) · Hepatology Communications · doi:10.1002/hep4.1997 · Cited by 36
“hAAT levels in the cell culture medium were detected by enzyme- linked immunosorbent assay (ELISA), as described.[21] Briefly, ultra- high- binding polystyrene”
MethodSelf-citationHatipoglu, U. S., & Stoller, J. K. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.04.011 · Cited by 35
Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?
Bañuls, L., Pellicer, D., Castillo, S., Navarro‐García, M. M., Magallón, M., González, C., & Dasí, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082577 · Cited by 35
Current status of gene therapy for α-1 antitrypsin deficiency
Loring, H. S., & Flotte, T. R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.978854 · Cited by 34
“The success associated with IM rAAV1-AAT delivery in animal models set the stage for another first-in-human Phase I clinical trial, this one for IM rAAV1-AAT [57].”
BackgroundSelf-citationBrimijoin, S., Shen, X., Orson, F. M., & Kosten, T. R. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.1 · Cited by 33
Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3 -Mutant Dogs
Ye, G.-J., Komáromy, A. M., Zeiss, C., Calcedo, R., Harman, C. D., Koehl, K. L., Stewart, G. A., Iwabe, S., Chiodo, V. A., Hauswirth, W. W., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.125 · Cited by 28
“Cellmediated immune responses to AAV capsid and hCNGB3 peptides were evaluated by measuring interferon gamma ELISPOT responses in PBMC, as previously described.(35) ACKNOWLEDGMENTS”
MethodSelf-citationNuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Te, B., Anglin, C. M., Bridges, P. H., & Cottle, R. N. (2017) · PubMed Central · Cited by 33
Advances in Alpha-1 Antitrypsin Gene Therapy
Lőrincz, R., & Curiel, D. T. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0159ps · Cited by 33
“Of note in this regard, the host’s immune response to the AAV can be dependent on the AAV serotype, the dose, the route of administration, and the transgene itself, as well as on the species being studied (28, 31).”
BackgroundProgress in Respiratory Gene Therapy
McLachlan, G., Alton, E. W. F. W., Boyd, A., Clarke, N. K., Davies, J. C., Gill, D. R., Griesenbach, U., Hickmott, J. W., Hyde, S. C., Miah, K. M., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.172 · Cited by 33
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what’s down the road?
Rahaghi, F. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211014025 · Cited by 33
Schnepp, B. C., Chulay, J. D., Ye, G., Flotte, T. R., Trapnell, B. C., & Johnson, P. R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.136 · Cited by 32
Self-citationAbdel‐Motal, U. M., Sarkis, P. T. N., Han, T. K., Pudney, J., Anderson, D. J., Zhu, Q. K., & Marasco, W. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026473 · Cited by 31
“Adeno-associated viral (AAV) vectors are capable of transducing a variety of tissues and cell types [17,18,19,20,21,22] with the potential of directing long-term expression from months to years since the vector persists predominantly in episomal form [17,19,21,23].”
BackgroundGene and cell therapy based treatment strategies for inflammatory bowel diseases
van der Marel, S., Majowicz, A., van Deventer, S., Petry, H., Hommes, D. W., & Ferreira, V. (2011) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v2.i6.114 · Cited by 32
Raj, D., Davidoff, A. M., & Nathwani, A. C. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.48 · Cited by 27
Kauss, M. A., Smith, L. J., Zhong, L., Srivastava, A., Wong, K. K., & Chatterjee, S. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.016 · Cited by 30
“…Giraud, 1996; Bell et al. , 2005), including their ability to transduce nondividing primary cells (Podsakoff et al. , 1994; Kaplitt et al. , 2007; Brantly et al. , 2009; Kells et al. , 2009; Towne et al. , 2010) and direct sustained transgene expression in vivo (Kessler et al. , 1996; Brantly…”
InfluentialLi, H., Tuyishime, S., Wu, T.-L., Giles-Davis, W., Zhou, D., Xiao, W., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.267 · Cited by 30
“Subsequent clinical trials confirmed that AAV vectors given at high doses for gene transfer augment frequencies of AAV capsid-specific CDp T cells circulating in the recipients' blood”
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies
Hua, C. K., & Ackerman, M. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01655 · Cited by 29
Haughan, J. E., Jiang, Z., Stefanovski, D., Moss, K. L., Ortved, K. F., & Robinson, M. A. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2785 · Cited by 29
Gene therapy for alpha-1 antitrypsin deficiency: an update
Pires-Ferreira, D., Gruntman, A. M., & Flotte, T. R. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2183771 · Cited by 29
“Also, a positive T cell response to the AAV1 capsid epitope was detected, but no immune response against the AAT transgene was observed [40].”
BackgroundSelf-citationTseng, Y.-S., Vliet, K. V., Rao, L., McKenna, R., Byrne, B. J., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.07.009 · Cited by 28
“…lipoprotein lipase deficiency (Pollack 2012), and numerous clinical trials are in progress for many other disease targets (Bainbridge et al. 2008; Brantly et al. 2009; Daniel Gaudet 2012; Ginn et al. 2013; Maguire et al. 2009; Maguire et al. 2008; Mendell et al. 2009; Smith et al. 2013;…”
BackgroundSelf-citationImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
“13,17,24 Interestingly, Mueller et al. showed the persistence of AAV capsids at the site of injection for up to 12 months after vector administration.”
Chotirmall, S. H., Al‐Alawi, M., McEnery, T., & McElvaney, N. G. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s51474 · Cited by 28
“Sustained AAT levels at 12 months have now been proven and Phase II clinical trials show promise.(54,55) Additionally, evidence by Brigham et al(56) illustrate that plasmid–cationic liposomal delivery of a normal AAT gene to the respiratory epithelium of deficient patients produces potentially local therapeutic AAT co…”
Exploiting Natural Diversity of AAV for the Design of Vectors with Novel Properties
Gao, G., Li, Z., & Danos, O. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_4 · Cited by 28
Moreau, A., Vandamme, C., Segovia, M., Devaux, M., Guilbaud, M., Tilly, G., Jaulin, N., Duff, J. L., Chérel, Y., Deschamps, J., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.28 · Cited by 28
Expert opinion in biological therapy: update on developments in lung gene transfer
Griesenbach, U., & Alton, E. W. F. W. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.735656 · Cited by 27
“In these the viral vector (either AAV2 or in later studies AAV1 serotypes) carrying the AAT cDNA were injected into skeletal muscle of trial subjects and the protein was secreted into the circulation [84-86].”
MethodGreene, C. M., Hassan, T. M., Molloy, K., & McElvaney, N. G. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.20 · Cited by 27
“have been carried out using non-viral, lentiviral and adeno-associated viral approaches to express the normal gene either locally or intramuscularly [171-176].”
MethodThe emerging role of viral vectors as vehicles for DMD gene editing
Maggio, I., Chen, X., & Gonçalves, M. A. F. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0316-x · Cited by 28
“This type of dosedependent cellular immune response has also been documented in human skeletal muscle cells transduced with rAAVs [60], although it is of note that the emergence of T-cell responses directed against rAAV capsid epitopes does not always equate with the elimination of transduced muscle cells [61].”
Lytle, A. M., Brown, H. C., Paik, N. Y., Knight, K. A., Wright, J. F., Spencer, H. T., & Doering, C. B. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.56 · Cited by 25
Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease
Stiles, K. M., Sondhi, D., Kaminsky, S. M., De, B. P., Rosenberg, J. B., & Crystal, R. G. (2018) · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · doi:10.15326/jcopdf.5.4.2017.0160 · Cited by 25
Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management
Santos, G., & Turner, A. M. (2020) · Faculty Reviews · doi:10.12703/b/9-1 · Cited by 25
Flotte, T. R. (2013) · Molecular Therapy · doi:10.1038/mt.2013.226 · Cited by 25
Self-citationZielińska, A., Eder, P., Karczewski, J., Szalata, M., Hryhorowicz, S., Wielgus, K., Szalata, M., Dobrowolska, A., Atanasov, A. G., Słomski, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147991 · Cited by 24
“After using adenovirus as a delivery vector, nowadays mainly for in vivo gene therapy, adenoassociated viruses (AAVs) are used and in vitro modification lentiviruses, for example, in chimeric antigen receptor (CAR) T cells (85, 86).”
MethodBourdon, A., François, V., Zhang, L., Lafoux, A., Fraysse, B., Toumaniantz, G., Larcher, T., Girard, T., Ledevin, M., Lebreton, C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00317-6 · Cited by 24
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
Fuchs, S. P., Martinez-Navío, J. M., Gao, G., & Desrosiers, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158009 · Cited by 23
“If the administered AAV vector dose is too high, anti-AAV capsid immune responses can negatively influence the outcome of AAV-mediated gene transfer leading to a loss of efficacy [10,41,48,49].”
BackgroundDetection of EPO gene doping in blood
Neuberger, E. W. I., Jurkiewicz, M., Moser, D., & Simon, P. D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1347 · Cited by 23
Optogenetic surface stimulation of the rat cervical spinal cord
Mondello, S. E., Sunshine, M. D., Fischedick, A. E., Dreyer, S. J., Horwitz, G. D., Anikeeva, P., Horner, P. J., & Moritz, C. T. (2018) · Journal of Neurophysiology · doi:10.1152/jn.00461.2017 · Cited by 23
“Although optogenetic transduction in humans is still somewhat controversial, there have been multiple clinical trials using AAV administration that have been successful with minimal side effects (Brantly et al. 2009; Flotte et al. 2011; Jaski et al. 2009; Nathwani et al. 2011; Stroes et al. 2008).”
MethodChiuchiolo, M. J., Kaminsky, S. M., Sondhi, D., Mancenido, D., Hollmann, C., & Crystal, R. G. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.2513 · Cited by 23
“…in using skeletal muscle and liver as the sites of gene transfer for the respiratory manifestations of a 1AT deficiency (Song et al. , 1998, 2001, 2002; Lu et al. , 2004, 2006; Brantly et al. , 2009; Chulay et al. , 2011; Flotte and Mueller, 2011; Flotte et al. , 2011; Mueller and Flotte, 2013).”
InfluentialCramer, M. L., Shao, G., Rodino-Klapac, L. R., Chicoine, L. G., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.113 · Cited by 22
“showed that patients with a1 anti-trypsin (AAT) deficiency treated by intramuscular injection of AAV1-AAT were able to maintain transgene expression a year after injection, despite the presence of T-cell responses to rAAV1 capsid peptides.(5) Thus, some tolerance or exhaustion may occur in AAV-targeted”
BackgroundKeeler, A. M., & Flotte, T. R. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.087 · Cited by 22
“Subsequently, both phase 1 and phase 2 trials of rAAV1-AAT IM delivery have been performed (Brantly et al., 2009; Flotte et al., 2011).”
BackgroundResultSelf-citationQiao, C., Yuan, Z., Li, J., Tang, R., Li, J., & Xiao, X. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.229 · Cited by 22
“AAV2 was the first AAV serotype that was made into vectors for gene transfer in preclinical and clinical applications (Samulski et al., 1982; Xiao et al., 1999; Flotte et al., 2003; Brantly et al., 2009).”
BackgroundConlon, T. J., Erger, K. E., Porvasnik, S., Cossette, T. L., Roberts, C., Combee, L. A., Islam, S., Kelley, J. S., Cloutier, D., Clément, N., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.147 · Cited by 21
Self-citationDatta, S., Renwick, M., Chau, V. Q., Zhang, F., Nettesheim, E. R., Lipinski, D. M., & Hulleman, J. D. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24987 · Cited by 21
Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy
Wozniak, J., Wandtke, T., Kopinski, P., & Chorostowska‐Wynimko, J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.044 · Cited by 21
“For this reason, the study was stopped and resumed 2 years later in 2011.(15,16,92) The same vector was applied but this time the herpes simplex virus complementation method was used.”
BackgroundMethodLi, H., Lu, Y., Witek, R. P., Chang, L., Campbell‐Thompson, M., Jorgensen, M., Petersen, B. E., & Song, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.116 · Cited by 21
Selot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20
“A similar immunogenic response to AAV is evident from other clinical trials as well (Mcphee et al., 2006; Brantly et al., 2009).”
BackgroundGene Therapy Cargoes Based on Viral Vector Delivery
Lundstrom, K. H. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220921112753 · Cited by 20
Gene Replacement Therapy for Genetic Hepatocellular Jaundice
van Dijk, R., Beuers, U. H., & Bosma, P. J. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8454-7 · Cited by 21
Adeno-Associated Viral Gene Delivery in Neurodegenerative Disease
Morgenstern, P. F., Marongiu, R., Musatov, S. A., & Kaplitt, M. G. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-328-8_29 · Cited by 20
Bioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle
Paulk, N. K., Pekrun, K., Charville, G. W., Maguire, K., Wosczyna, M. N., Xu, J., Zhang, Y., Lisowski, L., Yoo, B., Vilches-Moure, J. G., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.001 · Cited by 21
Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
Sosulski, M. L., Stiles, K. M., Frenk, E. Z., Hart, F. M., Matsumura, Y., De, B. P., Kaminsky, S. M., & Crystal, R. G. (2020) · JCI Insight · doi:10.1172/jci.insight.135951 · Cited by 20
“While these levels have not been achieved in AAT gene therapy clinical trials to date (59, 60, 63, 68), these calculations are based on WT AAT, a portion of which may be inactivated by oxidation.”
BackgroundExperimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency
Pye, A., & Turner, A. M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1672656 · Cited by 19
Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model
Greig, J. A., Jennis, M., Dandekar, A. P., Chorazeczewski, J. K., Smith, M. K., Ashley, S. N., Yan, H., & Wilson, J. M. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.08.003 · Cited by 19
Self-citationAlpha-1 antitrypsin deficiency: current therapy and emerging targets
McElvaney, O. F., Fraughen, D. D., McElvaney, O. J., Carroll, T. P., & McElvaney, N. G. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2174973 · Cited by 19
“Patients developed neutralizing antibodies against the AAV capsid but the expression lasted for up to one year [72].”
BackgroundGoodrich, L. R., McIlwraith, C. W., Grieger, J., Kraus, V. B., Stäbler, T., Werpy, N. M., Phillips, J., Samulski, R. J., & Frisbie, D. D. (2024) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.24.02.0078 · Cited by 18
“…AAV and specifically scAAV can be mild immunogens, 43,44 when T-cell responses have been identified in clinical trials, such as Brantly et al, 45 the protein expression from the transgene was not inhibited, suggesting that the presence of T lymphocytes did not mount a destructive effect on…”
Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain
Quintino, L., Namislo, A., Davidsson, M., Breger, L. S., Kavanagh, P., Avallone, M., Wettergren, E. E., Isaksson, C., & Lundberg, C. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.008 · Cited by 18
Metadata
- Authors
- Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. J., Wilson, J. M., & Flotte, T. R.
- Affiliations
- University of Florida (US)
- Applied Genetic Technologies (United States) (US)
- University of Pennsylvania (US)
- University of Massachusetts Chan Medical School (US)
- Boston Children's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-09-22
- Volume
- 106
- Issue
- 38
- Pages
- 16363-16368
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2752529
- OpenAlex
- W2083867423
- Cited by
- 327
- References
- 31
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 13 · 2020: 11 · 2019: 16 · 2018: 12 · 2017: 20 · 2016: 21 · 2015: 19 · 2014: 24 · 2013: 24 · 2012: 27
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- University of Florida
- Applied Genetic Technologies Corporation
- National Institutes of Health (and K24, DK047757)
- National Heart, Lung, and Blood Institute (R01HL69877, P01HL059412, R01HL069877, K24HL004456, K24 HL004456-5)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, P30DK047757, DK58327, DK047757-15)
- National Center for Research Resources (U42RR016586, M01RR000082)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- alpha-1 antitrypsin deficiency, T cell response, neutralizing antibodies, interferon-gamma, sustained transgene expression, dose escalation
- MeSH terms
- Dependovirus, Adult, Aged, alpha 1-Antitrypsin, Antibodies, Viral, Capsid, Cell Line, Enzyme-Linked Immunosorbent Assay, Female, Genetic Vectors, Humans, Injections, Intramuscular, Male, Middle Aged, Recombinant Fusion Proteins, T-Lymphocytes, Time Factors, Genetic Therapy, CD4-Positive T-Lymphocytes, Gene Expression, CD8-Positive T-Lymphocytes, alpha 1-Antitrypsin Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.